Advertisement

Nuclear Medicine and Molecular Imaging

, Volume 49, Issue 4, pp 284–290 | Cite as

Comparison of Diagnostic Sensitivity and Quantitative Indices Between 68Ga-DOTATOC PET/CT and 111In-Pentetreotide SPECT/CT in Neuroendocrine Tumors: a Preliminary Report

  • Inki Lee
  • Jin Chul Paeng
  • Soo Jin Lee
  • Chan Soo Shin
  • Jin-Young Jang
  • Gi Jeong Cheon
  • Dong Soo Lee
  • June-Key Chung
  • Keon Wook KangEmail author
Original Article

Abstract

Purpose

In-pentetreotide has been used for neuroendocrine tumors expressing somatostatin receptors. Recently, 68Ga-DOTATOC PET has been used with the advantage of high image quality. In this study, we compared quantitative indices between 111In-pentetreotide SPECT/CT and 68Ga-DOTATOC PET/CT.

Methods

Thirteen patients diagnosed with neuroendocrine tumors were prospectively recruited. Patients underwent 111In-pentetreotide scans with SPECT/CT and 68Ga-DOTATOC PET/CT before treatment. The number and location of lesions were analyzed on both imaging techniques to compare lesion detectability. Additionally, the maximal uptake count of each lesion and mean uptake count of the lungs were measured on both imagings, and target-to-normal lung ratios (TNR) were calculated as quantitative indices.

Results

Among 13 patients, 10 exhibited lesions with increased uptake on 111In-pentetreotide SPECT/CT and/or 68Ga-DOTATOC PET/CT. Scans with SPECT/CT detected 19 lesions, all of which were also detected on PET/CT. Moreover, 16 additional lesions were detected on PET/CT (6 in the liver, 9 in the pancreas and 1 in the spleen). PET/CT exhibited a significantly higher sensitivity than SPECT/CT (100 % vs. 54 %, P < 0.001). TNR was significantly higher on PET/CT than on SPECT/CT (99.9 ± 84.3 vs. 71.1 ± 114.9, P < 0.001) in spite of a significant correlation (r = 0.692, P = 0.01).

Conclusion

Ga-DOTATOC PET/CT has a higher diagnostic sensitivity than 111In-pentetreotide scans with SPECT/CT. The TNR on PET/CT is higher than that of SPECT/CT, which also suggests the higher sensitivity of PET/CT. 111In-pentetreotide SPECT/CT should be used carefully if it is used instead of 68Ga-DOTATOC PET/CT.

Keywords

Neuroendocrine tumors 68Ga-DOTATOC 111In-pentetreotide Positron emission tomography Single-photon emission-computed tomography 

Notes

Acknowledgments

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (no. NRF-2014M2A2A6049855)

Conflict of Interest

Inki Lee, Jin Chul Paeng, Soo Jin Lee, Chan Soo Shin, Jin-Young Jang, Gi Jeong Cheon, Dong Soo Lee, June-Key Chung and Keon Wook Kang declare that they have no conflict of interest.

Ethics Statement

This prospective study was approved by the Institutional Review Board at Seoul National University Hospital (IRB no. 1404-095-573), and all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards

References

  1. 1.
    Barbieri F, Albertelli M, Grillo F, Mohamed A, Saveanu A, Barlier A, et al. Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. Drug Discov Today. 2014;19(4):458–68.CrossRefPubMedGoogle Scholar
  2. 2.
    Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012;42(1):80–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113(10):2655–64.CrossRefPubMedGoogle Scholar
  4. 4.
    Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21(3):R153–63.CrossRefPubMedGoogle Scholar
  5. 5.
    Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Bar-Shalom R, Engel A, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf). 2003;59(5):565–73.CrossRefGoogle Scholar
  6. 6.
    Naswa N, Sharma P, Soundararajan R, Karunanithi S, Nazar AH, Kumar R, et al. Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings. Abdom Imaging. 2013;38(3):552–60.CrossRefPubMedGoogle Scholar
  7. 7.
    Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34(10):1617–26.CrossRefPubMedGoogle Scholar
  8. 8.
    Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci. 1995;16(3):86–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Kubota K, Okasaki M, Minamimoto R, Miyata Y, Morooka M, Nakajima K, et al. Lesion-based analysis of 18F-FDG uptake and 111In-pentetreotide uptake by neuroendocrine tumors. Ann Nucl Med. 2014;28(10):1004–10.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Etchebehere EC, de Oliveira SA, Gumz B, Vicente A, Hoff PG, Corradi G, et al. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J Nucl Med. 2014;55(10):1598–604.CrossRefPubMedGoogle Scholar
  11. 11.
    Schreiter NF, Bartels AM, Froeling V, Steffen I, Pape UF, Beck A, et al. Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT. Radiol Oncol. 2014;48(4):339–47.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Wangberg B, Nilsson O, Johanson VV, Kolby L, Forssell-Aronsson E, Andersson P, et al. Somatostatin receptors in the diagnosis and therapy of neuroendocrine tumor. Oncologist. 1997;2(1):50–8.PubMedGoogle Scholar
  13. 13.
    Schreiter NF, Brenner W, Nogami M, Buchert R, Huppertz A, Pape UF, et al. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(1):72–82.CrossRefPubMedGoogle Scholar
  14. 14.
    Johnbeck CB, Knigge U, Kjaer A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10(14):2259–77.CrossRefPubMedGoogle Scholar
  15. 15.
    Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273–82.CrossRefPubMedGoogle Scholar
  16. 16.
    Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51(5):669–73.CrossRefPubMedGoogle Scholar
  17. 17.
    Tan TH, Lee BN, Hassan SZ. Diagnostic value of 68Ga-DOTATATE PET/CT in liver metastases of neuroendocrine tumours of unknown origin. Nucl Med Mol Imaging. 2014;48(3):212–5.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, et al. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician’s perspective. J Nucl Med. 2015;56(1):70–5.CrossRefPubMedGoogle Scholar
  19. 19.
    van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwekkeboom DJ. GEPNETs UPDATE: radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol. 2015;172(1):R1–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, et al. SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol. 2015;17(3):313–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Kim YI, Cheon GJ, Paeng JC, Cho JY, Kang KW, Chung JK, et al. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma. Nucl Med Commun. 2014;35(6):606–12.CrossRefPubMedGoogle Scholar
  22. 22.
    Eo JS, Paeng JC, Lee DS. Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation. World J Gastroenterol. 2014;20(18):5375–88.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Sharma P, Singh H, Bal C, Kumar R. PET/CT imaging of neuroendocrine tumors with 68Gallium-labeled somatostatin analogues: an overview and single institutional experience from India. Indian J Nucl Med. 2014;29(1):2–12.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Nakahara T, Togawa T, Nagata M, Kikuchi K, Hatano K, Yui N, et al. Comparison of barium swallow, CT and thallium-201 SPECT in evaluating responses of patients with esophageal squamous cell carcinoma to preoperative chemoradiotherapy. Ann Nucl Med. 2003;17(7):583–91.CrossRefPubMedGoogle Scholar
  25. 25.
    Amano S, Inoue T, Tomiyoshi K, Ando T, Endo K. In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. J Nucl Med. 1998;39(8):1424–7.PubMedGoogle Scholar
  26. 26.
    Lastoria S, Vergara E, Palmieri G, Acampa W, Varrella P, Caraco C, et al. In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy. J Nucl Med. 1998;39(4):634–9.PubMedGoogle Scholar
  27. 27.
    Lebtahi R, Moreau S, Marchand-Adam S, Debray MP, Brauner M, Soler P, et al. Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med. 2006;47(8):1281–7.PubMedGoogle Scholar
  28. 28.
    Flux G, Bardies M, Monsieurs M, Savolainen S, Strands SE, Lassmann M. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Phys. 2006;16(1):47–59.CrossRefPubMedGoogle Scholar

Copyright information

© Korean Society of Nuclear Medicine 2015

Authors and Affiliations

  • Inki Lee
    • 1
  • Jin Chul Paeng
    • 1
  • Soo Jin Lee
    • 1
  • Chan Soo Shin
    • 2
  • Jin-Young Jang
    • 3
  • Gi Jeong Cheon
    • 1
    • 4
  • Dong Soo Lee
    • 1
    • 5
  • June-Key Chung
    • 1
    • 4
  • Keon Wook Kang
    • 1
    • 4
    Email author
  1. 1.Department of Nuclear MedicineSeoul National University College of MedicineSeoulKorea
  2. 2.Department of Internal MedicineSeoul National University College of MedicineSeoulKorea
  3. 3.Department of SurgerySeoul National University College of MedicineSeoulKorea
  4. 4.Cancer Research InstituteSeoul National UniversitySeoulKorea
  5. 5.Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and TechnologySeoul National UniversityGyeonggi-DoKorea

Personalised recommendations